Medipharm Labs (OTCMKTS:MLCPF) is a Canadian-based company specializing in the extraction, purification and formulation of cannabinoid-based products for a variety of end markets, including pharmaceuticals, wellness and pet care. Leveraging proprietary chromatography and distillation technologies, Medipharm Labs supplies ultra-pure cannabinoids, such as CBD and THC isolates, as well as tailored formulations designed to address specific therapeutic, nutritional and lifestyle applications. The company’s contract development and manufacturing services (CDMO) model supports white-label and branded customers seeking to scale production while adhering to rigorous quality standards.
Since its founding in 2015, Medipharm Labs has focused on establishing a vertically integrated platform that spans research and development, large-scale extraction, and finished dosage form manufacturing. The firm operates a state-of-the-art facility in Barrie, Ontario, which is certified to Good Manufacturing Practices (GMP) for both dietary supplements and pharmaceuticals. In addition to its Canadian base, Medipharm Labs extends its reach through international subsidiaries and partnerships in Europe, Australia and the United Kingdom, ensuring reliable supply chains for global brand owners and pharmaceutical companies.
Medipharm Labs’ product portfolio encompasses cannabinoid isolates, distillates, nanoemulsion solutions, topical creams, and oral dosage forms such as oils, capsules and softgels. The company also offers custom formulation services, helping clients optimize bioavailability, flavor and stability in their final products. This flexibility allows Medipharm Labs to serve a broad spectrum of customers, from emerging consumer wellness brands to established pharmaceutical enterprises seeking regulatory-compliant active ingredients.
Led by CEO Devin Crain, Medipharm Labs places strong emphasis on regulatory compliance, research collaborations and continuous process innovation. The senior management team brings extensive experience from the pharmaceutical, biotech and consumer packaged goods industries, positioning the company to capitalize on the evolving legal frameworks and growing demand for premium cannabinoid products. Through strategic capacity expansions and ongoing R&D investment, Medipharm Labs aims to maintain its competitive edge in the fast-growing global cannabinoid market.
AI Generated. May Contain Errors.
